A bibliometric insight into nanomaterials in vaccine: trends, collaborations, and future avenues
The emergence of nanotechnology has injected new vigor into vaccine research. Nanovaccine research has witnessed exponential growth in recent years; yet, a comprehensive analysis of related publications has been notably absent. This study utilizes bibliometric methodologies to reveal the evolution o...
Saved in:
| Published in | Frontiers in immunology Vol. 15; p. 1420216 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
Frontiers Media S.A
12.08.2024
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The emergence of nanotechnology has injected new vigor into vaccine research. Nanovaccine research has witnessed exponential growth in recent years; yet, a comprehensive analysis of related publications has been notably absent.
This study utilizes bibliometric methodologies to reveal the evolution of themes and the distribution of nanovaccine research.
Using tools such as VOSviewer, CiteSpace, Scimago Graphica, Pajek, R-bibliometrix, and R packages for the bibliometric analysis and visualization of literature retrieved from the Web of Science database.
Nanovaccine research commenced in 1981. The publication volume exponentially increased, notably in 2021. Leading contributors include the United States, the Chinese Academy of Sciences, the "
", and researcher Zhao Kai. Other significant contributors comprise China, the University of California, San Diego, Veronique Preat, the
, and the National Natural Science Foundation of China. The USA functions as a central hub for international cooperation. Financial support plays a pivotal role in driving research advancements. Key themes in highly cited articles include vaccine carrier design, cancer vaccines, nanomaterial properties, and COVID-19 vaccines. Among 7402 keywords, the principal nanocarriers include Chitosan, virus-like particles, gold nanoparticles, PLGA, and lipid nanoparticles. Nanovaccine is primarily intended to address diseases including SARS-CoV-2, cancer, influenza, and HIV. Clustering analysis of co-citation networks identifies 9 primary clusters, vividly illustrating the evolution of research themes over different periods. Co-citation bursts indicate that cancer vaccines, COVID-19 vaccines, and mRNA vaccines are pivotal areas of focus for current and future research in nanovaccines. "candidate vaccines," "protein nanoparticle," "cationic lipids," "ionizable lipids," "machine learning," "long-term storage," "personalized cancer vaccines," "neoantigens," "outer membrane vesicles," "
nanovaccine," and "biomimetic nanotechnologies" stand out as research interest.
This analysis emphasizes the increasing scholarly interest in nanovaccine research and highlights pivotal recent research themes such as cancer and COVID-19 vaccines, with lipid nanoparticle-mRNA vaccines leading novel research directions. |
|---|---|
| AbstractList | BackgroundThe emergence of nanotechnology has injected new vigor into vaccine research. Nanovaccine research has witnessed exponential growth in recent years; yet, a comprehensive analysis of related publications has been notably absent.ObjectiveThis study utilizes bibliometric methodologies to reveal the evolution of themes and the distribution of nanovaccine research.MethodsUsing tools such as VOSviewer, CiteSpace, Scimago Graphica, Pajek, R-bibliometrix, and R packages for the bibliometric analysis and visualization of literature retrieved from the Web of Science database.ResultsNanovaccine research commenced in 1981. The publication volume exponentially increased, notably in 2021. Leading contributors include the United States, the Chinese Academy of Sciences, the “Vaccine”, and researcher Zhao Kai. Other significant contributors comprise China, the University of California, San Diego, Veronique Preat, the Journal of Controlled Release, and the National Natural Science Foundation of China. The USA functions as a central hub for international cooperation. Financial support plays a pivotal role in driving research advancements. Key themes in highly cited articles include vaccine carrier design, cancer vaccines, nanomaterial properties, and COVID-19 vaccines. Among 7402 keywords, the principal nanocarriers include Chitosan, virus-like particles, gold nanoparticles, PLGA, and lipid nanoparticles. Nanovaccine is primarily intended to address diseases including SARS-CoV-2, cancer, influenza, and HIV. Clustering analysis of co-citation networks identifies 9 primary clusters, vividly illustrating the evolution of research themes over different periods. Co-citation bursts indicate that cancer vaccines, COVID-19 vaccines, and mRNA vaccines are pivotal areas of focus for current and future research in nanovaccines. “candidate vaccines,” “protein nanoparticle,” “cationic lipids,” “ionizable lipids,” “machine learning,” “long-term storage,” “personalized cancer vaccines,” “neoantigens,” “outer membrane vesicles,” “in situ nanovaccine,” and “biomimetic nanotechnologies” stand out as research interest.ConclusionsThis analysis emphasizes the increasing scholarly interest in nanovaccine research and highlights pivotal recent research themes such as cancer and COVID-19 vaccines, with lipid nanoparticle-mRNA vaccines leading novel research directions. The emergence of nanotechnology has injected new vigor into vaccine research. Nanovaccine research has witnessed exponential growth in recent years; yet, a comprehensive analysis of related publications has been notably absent. This study utilizes bibliometric methodologies to reveal the evolution of themes and the distribution of nanovaccine research. Using tools such as VOSviewer, CiteSpace, Scimago Graphica, Pajek, R-bibliometrix, and R packages for the bibliometric analysis and visualization of literature retrieved from the Web of Science database. Nanovaccine research commenced in 1981. The publication volume exponentially increased, notably in 2021. Leading contributors include the United States, the Chinese Academy of Sciences, the " ", and researcher Zhao Kai. Other significant contributors comprise China, the University of California, San Diego, Veronique Preat, the , and the National Natural Science Foundation of China. The USA functions as a central hub for international cooperation. Financial support plays a pivotal role in driving research advancements. Key themes in highly cited articles include vaccine carrier design, cancer vaccines, nanomaterial properties, and COVID-19 vaccines. Among 7402 keywords, the principal nanocarriers include Chitosan, virus-like particles, gold nanoparticles, PLGA, and lipid nanoparticles. Nanovaccine is primarily intended to address diseases including SARS-CoV-2, cancer, influenza, and HIV. Clustering analysis of co-citation networks identifies 9 primary clusters, vividly illustrating the evolution of research themes over different periods. Co-citation bursts indicate that cancer vaccines, COVID-19 vaccines, and mRNA vaccines are pivotal areas of focus for current and future research in nanovaccines. "candidate vaccines," "protein nanoparticle," "cationic lipids," "ionizable lipids," "machine learning," "long-term storage," "personalized cancer vaccines," "neoantigens," "outer membrane vesicles," " nanovaccine," and "biomimetic nanotechnologies" stand out as research interest. This analysis emphasizes the increasing scholarly interest in nanovaccine research and highlights pivotal recent research themes such as cancer and COVID-19 vaccines, with lipid nanoparticle-mRNA vaccines leading novel research directions. The emergence of nanotechnology has injected new vigor into vaccine research. Nanovaccine research has witnessed exponential growth in recent years; yet, a comprehensive analysis of related publications has been notably absent.BackgroundThe emergence of nanotechnology has injected new vigor into vaccine research. Nanovaccine research has witnessed exponential growth in recent years; yet, a comprehensive analysis of related publications has been notably absent.This study utilizes bibliometric methodologies to reveal the evolution of themes and the distribution of nanovaccine research.ObjectiveThis study utilizes bibliometric methodologies to reveal the evolution of themes and the distribution of nanovaccine research.Using tools such as VOSviewer, CiteSpace, Scimago Graphica, Pajek, R-bibliometrix, and R packages for the bibliometric analysis and visualization of literature retrieved from the Web of Science database.MethodsUsing tools such as VOSviewer, CiteSpace, Scimago Graphica, Pajek, R-bibliometrix, and R packages for the bibliometric analysis and visualization of literature retrieved from the Web of Science database.Nanovaccine research commenced in 1981. The publication volume exponentially increased, notably in 2021. Leading contributors include the United States, the Chinese Academy of Sciences, the "Vaccine", and researcher Zhao Kai. Other significant contributors comprise China, the University of California, San Diego, Veronique Preat, the Journal of Controlled Release, and the National Natural Science Foundation of China. The USA functions as a central hub for international cooperation. Financial support plays a pivotal role in driving research advancements. Key themes in highly cited articles include vaccine carrier design, cancer vaccines, nanomaterial properties, and COVID-19 vaccines. Among 7402 keywords, the principal nanocarriers include Chitosan, virus-like particles, gold nanoparticles, PLGA, and lipid nanoparticles. Nanovaccine is primarily intended to address diseases including SARS-CoV-2, cancer, influenza, and HIV. Clustering analysis of co-citation networks identifies 9 primary clusters, vividly illustrating the evolution of research themes over different periods. Co-citation bursts indicate that cancer vaccines, COVID-19 vaccines, and mRNA vaccines are pivotal areas of focus for current and future research in nanovaccines. "candidate vaccines," "protein nanoparticle," "cationic lipids," "ionizable lipids," "machine learning," "long-term storage," "personalized cancer vaccines," "neoantigens," "outer membrane vesicles," "in situ nanovaccine," and "biomimetic nanotechnologies" stand out as research interest.ResultsNanovaccine research commenced in 1981. The publication volume exponentially increased, notably in 2021. Leading contributors include the United States, the Chinese Academy of Sciences, the "Vaccine", and researcher Zhao Kai. Other significant contributors comprise China, the University of California, San Diego, Veronique Preat, the Journal of Controlled Release, and the National Natural Science Foundation of China. The USA functions as a central hub for international cooperation. Financial support plays a pivotal role in driving research advancements. Key themes in highly cited articles include vaccine carrier design, cancer vaccines, nanomaterial properties, and COVID-19 vaccines. Among 7402 keywords, the principal nanocarriers include Chitosan, virus-like particles, gold nanoparticles, PLGA, and lipid nanoparticles. Nanovaccine is primarily intended to address diseases including SARS-CoV-2, cancer, influenza, and HIV. Clustering analysis of co-citation networks identifies 9 primary clusters, vividly illustrating the evolution of research themes over different periods. Co-citation bursts indicate that cancer vaccines, COVID-19 vaccines, and mRNA vaccines are pivotal areas of focus for current and future research in nanovaccines. "candidate vaccines," "protein nanoparticle," "cationic lipids," "ionizable lipids," "machine learning," "long-term storage," "personalized cancer vaccines," "neoantigens," "outer membrane vesicles," "in situ nanovaccine," and "biomimetic nanotechnologies" stand out as research interest.This analysis emphasizes the increasing scholarly interest in nanovaccine research and highlights pivotal recent research themes such as cancer and COVID-19 vaccines, with lipid nanoparticle-mRNA vaccines leading novel research directions.ConclusionsThis analysis emphasizes the increasing scholarly interest in nanovaccine research and highlights pivotal recent research themes such as cancer and COVID-19 vaccines, with lipid nanoparticle-mRNA vaccines leading novel research directions. |
| Author | Zhang, Xuexue Wang, Xuejie Liu, Ye Qiao, Chen Wu, Beibei Liu, Jian Luo, Ding |
| AuthorAffiliation | 1 Department of Information, Xiyuan Hospital, China Academy of Chinese Medical Sciences , Beijing , China 4 Graduate School, Beijing University of Chinese Medicine , Beijing , China 3 Graduate School, China Academy of Chinese Medical Sciences , Beijing , China 2 Traditional Chinese Medicine (TCM) Big Data Innovation Lab of Beijing Office of Academic Research, Xiyuan Hospital, China Academy of Chinese Medical Sciences , Beijing , China |
| AuthorAffiliation_xml | – name: 3 Graduate School, China Academy of Chinese Medical Sciences , Beijing , China – name: 4 Graduate School, Beijing University of Chinese Medicine , Beijing , China – name: 1 Department of Information, Xiyuan Hospital, China Academy of Chinese Medical Sciences , Beijing , China – name: 2 Traditional Chinese Medicine (TCM) Big Data Innovation Lab of Beijing Office of Academic Research, Xiyuan Hospital, China Academy of Chinese Medical Sciences , Beijing , China |
| Author_xml | – sequence: 1 givenname: Beibei surname: Wu fullname: Wu, Beibei – sequence: 2 givenname: Ye surname: Liu fullname: Liu, Ye – sequence: 3 givenname: Xuexue surname: Zhang fullname: Zhang, Xuexue – sequence: 4 givenname: Ding surname: Luo fullname: Luo, Ding – sequence: 5 givenname: Xuejie surname: Wang fullname: Wang, Xuejie – sequence: 6 givenname: Chen surname: Qiao fullname: Qiao, Chen – sequence: 7 givenname: Jian surname: Liu fullname: Liu, Jian |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39188723$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVUstuFDEQtFAQCSE_wAHNkQO7-Dk75oKiiEekSFzgbNp2z8bRjB1sz0r8Pd7sEiX2odrtcrXVXa_JSUwRCXnL6FqIQX8cwzwva065XDPZgPUvyBnre7kSnMuTJ_EpuSjljrYltRBCvSKnQrNh2HBxRn5fdjbYKaQZaw6uC7GE7W1tWFMXIaYZKuYAU2mpbgfOhYifupox-vKhc2mawKYMNaTYzhB9Ny51ydjBDuOC5Q15ObbXeHHEc_Lr65efV99XNz--XV9d3qxc-31dKdcrpbgdrfZqpLa3Tlo3CMFGq6TTnPdao4Z-0NI7vUFJW6yYVANawUCck-uDrk9wZ-5zmCH_NQmCeUikvDWQa3ATGirAa8uoGzTIjW7bSiv9wP3otGCuaX0-aN0vdkbvMNYM0zPR5zcx3Jpt2hnGhFRM6abw_qiQ05_WhWrmUBy2ZkVMSzGC6s1-Gpw36runxR6r_J9RI_ADweVUSsbxkcKo2XvBPHjB7L1gjl4Q_wBr3Kj6 |
| Cites_doi | 10.1098/rstb.2013.0433 10.1038/32588 10.1016/j.jconrel.2022.09.044 10.1007/s11192-021-04061-3 10.1016/j.vaccine.2013.11.069 10.1016/j.cell.2020.02.052 10.1038/nature23003 10.3791/58494 10.1016/j.jconrel.2022.11.022 10.1126/scitranslmed.abi5735 10.2147/JPR.S340961 10.1002/adfm.202204692 10.1038/nnano.2015.292 10.1038/nrd.2017.243 10.1021/nn500216y 10.2174/156720111795256192 10.1158/1078-0432.CCR-11-1595 10.1016/j.jconrel.2015.08.007 10.1016/j.ymthe.2018.03.010 10.1016/j.cell.2020.02.058 10.1016/j.biomaterials.2021.120709 10.1016/j.nantod.2021.101142 10.18520/cs/v116/i11/1909-1914 10.1016/j.cell.2021.01.035 10.1021/acsnano.1c04996 10.1039/D2BM01432G 10.1016/j.scijus.2022.10.005 10.3390/vaccines9040359 10.1002/btm2.10213 10.1021/acsnano.5b01042 10.2174/1389201015666140909122727 10.1146/annurev-bioeng-110220-031722 10.3389/fonc.2023.1211262 10.1038/s41573-021-00283-5 10.1016/j.biomaterials.2023.122243 10.1038/nm.3161 10.1038/nnano.2017.52 10.1016/j.apsb.2021.11.021 10.4155/tde-2016-0006 10.1021/acs.nanolett.1c01353 10.1016/j.jconrel.2006.08.013 10.1038/s41565-019-0591-y 10.1016/j.xphs.2020.12.006 10.1038/s41563-020-0793-6 10.1038/nmat4822 10.1038/nature12978 10.1038/s41467-023-37417-9 10.1056/NEJMoa2027906 10.1038/s41586-021-04387-1 10.1126/scitranslmed.aao5931 10.1021/acs.nanolett.8b00478 10.1056/NEJMoa2001017 10.1002/adhm.202300524 10.1056/NEJMoa2035389 10.1038/nature22991 10.1021/acsnano.7b09041 10.1186/s12951-023-02033-8 10.1021/nl500618u 10.1126/science.abb2507 10.1016/j.ymthe.2017.03.035 10.1056/NEJMoa2034577 10.1016/j.omtn.2019.01.013 10.1016/S0140-6736(20)31208-3 10.1016/j.jconrel.2023.02.015 10.2217/nnm-2018-0147 10.1016/j.cell.2017.02.017 10.1016/j.actbio.2021.06.023 10.1016/j.jbusres.2022.04.042 10.1038/s41467-021-22308-8 10.1056/NEJMoa2026920 10.1038/s41590-020-00810-3 10.1016/j.ymthe.2022.02.001 10.1038/s41467-023-41661-4 10.1016/j.jbusres.2021.04.070 10.1038/d41586-021-00586-y 10.1002/adma.202209910 10.1158/1078-0432.CCR-17-2807 10.1016/j.eurpolymj.2017.02.014 |
| ContentType | Journal Article |
| Copyright | Copyright © 2024 Wu, Liu, Zhang, Luo, Wang, Qiao and Liu. Copyright © 2024 Wu, Liu, Zhang, Luo, Wang, Qiao and Liu 2024 Wu, Liu, Zhang, Luo, Wang, Qiao and Liu |
| Copyright_xml | – notice: Copyright © 2024 Wu, Liu, Zhang, Luo, Wang, Qiao and Liu. – notice: Copyright © 2024 Wu, Liu, Zhang, Luo, Wang, Qiao and Liu 2024 Wu, Liu, Zhang, Luo, Wang, Qiao and Liu |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.3389/fimmu.2024.1420216 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1664-3224 |
| ExternalDocumentID | oai_doaj_org_article_03ad9b10c89a479797b4b4d82dfc931c PMC11345159 39188723 10_3389_fimmu_2024_1420216 |
| Genre | Journal Article |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 PGMZT RNS RPM CGR CUY CVF ECM EIF IPNFZ NPM RIG 7X8 5PM |
| ID | FETCH-LOGICAL-c420t-5c65552bfb9d5f0b6bc4bc8331fb54c922699e9a6894dc97e40a6851458eb31a3 |
| IEDL.DBID | M48 |
| ISSN | 1664-3224 |
| IngestDate | Wed Aug 27 01:32:06 EDT 2025 Thu Aug 21 18:32:16 EDT 2025 Fri Jul 11 07:47:41 EDT 2025 Thu Apr 03 07:01:54 EDT 2025 Tue Jul 01 01:40:56 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | COVID-19 bibliometric lipid nanoparticles vaccine cancer nanoparticles |
| Language | English |
| License | Copyright © 2024 Wu, Liu, Zhang, Luo, Wang, Qiao and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c420t-5c65552bfb9d5f0b6bc4bc8331fb54c922699e9a6894dc97e40a6851458eb31a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Himanshu Gogoi, Translational Health Science and Technology Institute (THSTI), India Edited by: Roberto Adamo, GlaxoSmithKline, Italy Reviewed by: Prashant Sharma, University of Arizona, United States |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fimmu.2024.1420216 |
| PMID | 39188723 |
| PQID | 3097493322 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_03ad9b10c89a479797b4b4d82dfc931c pubmedcentral_primary_oai_pubmedcentral_nih_gov_11345159 proquest_miscellaneous_3097493322 pubmed_primary_39188723 crossref_primary_10_3389_fimmu_2024_1420216 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-08-12 |
| PublicationDateYYYYMMDD | 2024-08-12 |
| PublicationDate_xml | – month: 08 year: 2024 text: 2024-08-12 day: 12 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in immunology |
| PublicationTitleAlternate | Front Immunol |
| PublicationYear | 2024 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Donthu (B20) 2021; 133 Cele (B55) 2022; 602 Yi (B6) 2023; 355 Wang (B59) 2022; 12 Pardi (B33) 2015; 217 Baharom (B77) 2021; 22 des Rieux (B17) 2006; 116 Banchereau (B47) 1998; 392 González-Alcaide (B21) 2021; 126 Pilkington (B54) 2021; 131 Hassett (B39) 2019; 15 Ling (B26) 2023; 21 Yang (B32) 2018; 12 Baden (B8) 2021; 384 Chen (B74) 2023; 35 Zhao (B3) 2014; 32 Tenchov (B52) 2021; 15 Wen (B12) 2019; 14 Zhu (B44) 2020; 395 Cheng (B72) 2021; 12 Liu (B28) 2014; 507 Walsh (B46) 2020; 383 Robbins (B75) 2013; 19 Khurana (B53) 2021; 38 Guo (B71) 2015; 9 AlRyalat (B24) 2019; 152 Qiao (B50) 2018; 18 Weidenbacher (B65) 2023; 14 Muramatsu (B62) 2022; 30 Lipson (B67) 2011; 17 Abdullah (B19) 2023; 5 Reichmuth (B34) 2016; 7 Zhu (B40) 2020; 382 Wang (B69) 2023; 12 Goldman (B58) 2023; 301 Lizotte (B68) 2016; 11 Greenwood (B2) 2014; 369 Teng (B18) 2022; 351 Hutchinson (B64) 2023; 14 Zhao (B49) 2017; 93 Herreros (B5) 2014; 15 Chen (B11) 2021; 270 Pardi (B1) 2018; 17 Chen (B78) 2022; 24 Schlich (B56) 2021; 6 Akinc (B37) 2019; 14 Thi (B9) 2021; 9 Huang (B27) 2021; 14 Sabnis (B38) 2018; 26 Skwarczynski (B48) 2011; 8 Bahl (B35) 2017; 25 Liu (B79) 2021; 20 Mukherjee (B22) 2022; 148 Tanyi (B76) 2018; 21 Xu (B14) 2014; 8 Luo (B30) 2017; 12 Polack (B7) 2020; 383 Chen (B57) 2022; 32 Yao (B4) 2023; 13 Hoffmann (B43) 2020; 181 Brouwer (B63) 2021; 184 Kuai (B13) 2017; 16 Richner (B36) 2017; 168 Walls (B41) 2020; 181 Crommelin (B60) 2021; 110 Kim (B61) 2023; 353 Shepherd (B16) 2021; 21 Subbaraman (B51) 2021; 591 Shen (B23) 2023; 63 Joyce (B66) 2022; 14 Keech (B45) 2020; 383 Chaudhary (B15) 2021; 20 Sahin (B10) 2017; 547 Ott (B29) 2017; 547 Fang (B31) 2014; 14 Wang (B70) 2023; 11 Tan (B73) 2018; 24 Yeung (B25) 2019; 116 Wrapp (B42) 2020; 367 |
| References_xml | – volume: 369 start-page: 20130433 year: 2014 ident: B2 article-title: The contribution of vaccination to global health: past, present and future publication-title: Philos Trans R Soc Lond B Biol Sci doi: 10.1098/rstb.2013.0433 – volume: 392 year: 1998 ident: B47 article-title: Dendritic cells and the control of immunity publication-title: Nature doi: 10.1038/32588 – volume: 351 year: 2022 ident: B18 article-title: Bridging nanoplatform and vaccine delivery, a landscape of strategy to enhance nasal immunity publication-title: J Control Release doi: 10.1016/j.jconrel.2022.09.044 – volume: 126 year: 2021 ident: B21 article-title: Bibliometric studies outside the information science and library science field: uncontainable or uncontrollable publication-title: Scientometrics doi: 10.1007/s11192-021-04061-3 – volume: 32 year: 2014 ident: B3 article-title: Nanoparticle vaccines publication-title: Vaccine doi: 10.1016/j.vaccine.2013.11.069 – volume: 181 start-page: 271 year: 2020 ident: B43 article-title: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor publication-title: Cell doi: 10.1016/j.cell.2020.02.052 – volume: 547 year: 2017 ident: B10 article-title: Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer publication-title: Nature doi: 10.1038/nature23003 – volume: 152 year: 2019 ident: B24 article-title: Comparing bibliometric analysis using PubMed, scopus, and web of science databases publication-title: Jove J Visual Exp doi: 10.3791/58494 – volume: 353 year: 2023 ident: B61 article-title: Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines publication-title: J Control Release doi: 10.1016/j.jconrel.2022.11.022 – volume: 14 start-page: eabi5735 year: 2022 ident: B66 article-title: A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates publication-title: Sci Transl Med doi: 10.1126/scitranslmed.abi5735 – volume: 14 year: 2021 ident: B27 article-title: Bibliometric analysis of functional magnetic resonance imaging studies on acupuncture analgesia over the past 20 years publication-title: J Pain Res doi: 10.2147/JPR.S340961 – volume: 32 start-page: 2204692 year: 2022 ident: B57 article-title: mRNA vaccines against SARS-CoV-2 variants delivered by lipid nanoparticles based on novel ionizable lipids publication-title: Adv Funct Mater doi: 10.1002/adfm.202204692 – volume: 11 start-page: 295 year: 2016 ident: B68 article-title: In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer publication-title: Nat Nanotechnol doi: 10.1038/nnano.2015.292 – volume: 17 year: 2018 ident: B1 article-title: mRNA vaccines - a new era in vaccinology publication-title: Nat Rev Drug Discovery doi: 10.1038/nrd.2017.243 – volume: 8 year: 2014 ident: B14 article-title: Nanoparticle-Delivered Transforming Growth Factor-β siRNA Enhances Vaccination against Advanced Melanoma by Modifying Tumor Microenvironment publication-title: ACS Nano doi: 10.1021/nn500216y – volume: 8 year: 2011 ident: B48 article-title: Peptide-based subunit nanovaccines publication-title: Curr Drug Delivery doi: 10.2174/156720111795256192 – volume: 17 year: 2011 ident: B67 article-title: Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-1595 – volume: 217 year: 2015 ident: B33 article-title: Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes publication-title: J Control Release doi: 10.1016/j.jconrel.2015.08.007 – volume: 26 year: 2018 ident: B38 article-title: A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates publication-title: Mol Ther doi: 10.1016/j.ymthe.2018.03.010 – volume: 181 start-page: 281 year: 2020 ident: B41 article-title: Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein publication-title: Cell doi: 10.1016/j.cell.2020.02.058 – volume: 270 start-page: 120709 year: 2021 ident: B11 article-title: Nanobiomaterial-based vaccination immunotherapy of cancer publication-title: Biomaterials doi: 10.1016/j.biomaterials.2021.120709 – volume: 38 start-page: 101142 year: 2021 ident: B53 article-title: Role of nanotechnology behind the success of mRNA vaccines for COVID-19 publication-title: Nano Today doi: 10.1016/j.nantod.2021.101142 – volume: 116 year: 2019 ident: B25 article-title: Comparison between Scopus, Web of Science, PubMed and publishers for mislabelled review papers publication-title: Curr Sci doi: 10.18520/cs/v116/i11/1909-1914 – volume: 184 start-page: 1188 year: 2021 ident: B63 article-title: Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection publication-title: Cell doi: 10.1016/j.cell.2021.01.035 – volume: 15 year: 2021 ident: B52 article-title: Lipid nanoparticles-from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement publication-title: ACS Nano doi: 10.1021/acsnano.1c04996 – volume: 11 year: 2023 ident: B70 article-title: Trojan horse” nanoparticle-delivered cancer cell membrane vaccines to enhance cancer immunotherapy by overcoming immune-escape publication-title: Biomater Sci doi: 10.1039/D2BM01432G – volume: 63 start-page: 19 year: 2023 ident: B23 article-title: Mapping the knowledge of traffic collision Reconstruction: A scientometric analysis in CiteSpace, VOSviewer, and SciMAT publication-title: Sci Justice doi: 10.1016/j.scijus.2022.10.005 – volume: 9 start-page: 359 year: 2021 ident: B9 article-title: Lipid-based nanoparticles in the clinic and clinical trials: from cancer nanomedicine to COVID-19 vaccines publication-title: Vaccines (Basel) doi: 10.3390/vaccines9040359 – volume: 6 start-page: e10213 year: 2021 ident: B56 article-title: Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles publication-title: Bioeng Transl Med doi: 10.1002/btm2.10213 – volume: 9 year: 2015 ident: B71 article-title: Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma publication-title: ACS Nano doi: 10.1021/acsnano.5b01042 – volume: 15 year: 2014 ident: B5 article-title: Advances in nanomedicine towards clinical application in oncology and immunology publication-title: Curr Pharm Biotechnol doi: 10.2174/1389201015666140909122727 – volume: 24 start-page: 85 year: 2022 ident: B78 article-title: Current developments and challenges of mRNA vaccines publication-title: Annu Rev BioMed Eng doi: 10.1146/annurev-bioeng-110220-031722 – volume: 13 year: 2023 ident: B4 article-title: Research progress of nanovaccine in anti-tumor immunotherapy publication-title: Front Oncol doi: 10.3389/fonc.2023.1211262 – volume: 20 year: 2021 ident: B15 article-title: mRNA vaccines for infectious diseases: principles, delivery and clinical translation publication-title: Nat Rev Drug Discovery doi: 10.1038/s41573-021-00283-5 – volume: 301 start-page: 122243 year: 2023 ident: B58 article-title: Understanding structure activity relationships of Good HEPES lipids for lipid nanoparticle mRNA vaccine applications publication-title: Biomaterials doi: 10.1016/j.biomaterials.2023.122243 – volume: 19 year: 2013 ident: B75 article-title: Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells publication-title: Nat Med doi: 10.1038/nm.3161 – volume: 12 year: 2017 ident: B30 article-title: A STING-activating nanovaccine for cancer immunotherapy publication-title: Nat Nanotechnol doi: 10.1038/nnano.2017.52 – volume: 12 year: 2022 ident: B59 article-title: Prediction of lipid nanoparticles for mRNA vaccines by the machine learning algorithm publication-title: Acta Pharm Sin B doi: 10.1016/j.apsb.2021.11.021 – volume: 7 year: 2016 ident: B34 article-title: mRNA vaccine delivery using lipid nanoparticles publication-title: Ther Delivery doi: 10.4155/tde-2016-0006 – volume: 21 year: 2021 ident: B16 article-title: Scalable mRNA and siRNA Lipid Nanoparticle Production Using a Parallelized Microfluidic Device publication-title: Nano Lett doi: 10.1021/acs.nanolett.1c01353 – volume: 116 start-page: 1 year: 2006 ident: B17 article-title: Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach publication-title: J Control Release doi: 10.1016/j.jconrel.2006.08.013 – volume: 14 year: 2019 ident: B37 article-title: The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs publication-title: Nat Nanotechnol doi: 10.1038/s41565-019-0591-y – volume: 110 start-page: 997 year: 2021 ident: B60 article-title: Addressing the cold reality of mRNA vaccine stability publication-title: J Pharm Sci doi: 10.1016/j.xphs.2020.12.006 – volume: 20 year: 2021 ident: B79 article-title: A DNA nanodevice-based vaccine for cancer immunotherapy publication-title: Nat Mater doi: 10.1038/s41563-020-0793-6 – volume: 16 year: 2017 ident: B13 article-title: Designer vaccine nanodiscs for personalized cancer immunotherapy publication-title: Nat Mater doi: 10.1038/nmat4822 – volume: 507 year: 2014 ident: B28 article-title: Structure-based programming of lymph-node targeting in molecular vaccines publication-title: Nature doi: 10.1038/nature12978 – volume: 14 start-page: 2149 year: 2023 ident: B65 article-title: A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates publication-title: Nat Commun doi: 10.1038/s41467-023-37417-9 – volume: 383 year: 2020 ident: B46 article-title: Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates publication-title: N Engl J Med doi: 10.1056/NEJMoa2027906 – volume: 602 year: 2022 ident: B55 article-title: Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization publication-title: Nature doi: 10.1038/s41586-021-04387-1 – volume: 5 year: 2023 ident: B19 article-title: Unearthing hidden research opportunities through bibliometric analysis: a review publication-title: Asian J Res Educ Soc Sci – volume: 21 year: 2018 ident: B76 article-title: Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aao5931 – volume: 18 year: 2018 ident: B50 article-title: Potency of a scalable nanoparticulate subunit vaccine publication-title: Nano Lett doi: 10.1021/acs.nanolett.8b00478 – volume: 382 year: 2020 ident: B40 article-title: A novel coronavirus from patients with pneumonia in China, 2019 publication-title: N Eng J Med doi: 10.1056/NEJMoa2001017 – volume: 12 start-page: e2300524 year: 2023 ident: B69 article-title: Self-immolated nanoadjuvant for in situ vaccination immunotherapy of colorectal cancer publication-title: Adv Healthc Mater doi: 10.1002/adhm.202300524 – volume: 384 year: 2021 ident: B8 article-title: Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine publication-title: N Engl J Med doi: 10.1056/NEJMoa2035389 – volume: 547 year: 2017 ident: B29 article-title: An immunogenic personal neoantigen vaccine for patients with melanoma publication-title: Nature doi: 10.1038/nature22991 – volume: 12 year: 2018 ident: B32 article-title: Cancer cell membrane-coated adjuvant nanoparticles with mannose modification for effective anticancer vaccination publication-title: ACS Nano doi: 10.1021/acsnano.7b09041 – volume: 21 start-page: 248 year: 2023 ident: B26 article-title: Research trends on nanomaterials in gastric cancer: a bibliometric analysis from 2004 to 2023 publication-title: J Nanobiotechnol doi: 10.1186/s12951-023-02033-8 – volume: 14 year: 2014 ident: B31 article-title: Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery publication-title: Nano Lett doi: 10.1021/nl500618u – volume: 367 year: 2020 ident: B42 article-title: Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation publication-title: Science doi: 10.1126/science.abb2507 – volume: 25 year: 2017 ident: B35 article-title: Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses publication-title: Mol Ther doi: 10.1016/j.ymthe.2017.03.035 – volume: 383 year: 2020 ident: B7 article-title: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine publication-title: N Engl J Med doi: 10.1056/NEJMoa2034577 – volume: 15 start-page: 1 year: 2019 ident: B39 article-title: Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines publication-title: Mol Ther Nucleic Acids doi: 10.1016/j.omtn.2019.01.013 – volume: 395 year: 2020 ident: B44 article-title: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial publication-title: Lancet doi: 10.1016/S0140-6736(20)31208-3 – volume: 355 year: 2023 ident: B6 article-title: Vaccine-like nanomedicine for cancer immunotherapy publication-title: J Controlled Release doi: 10.1016/j.jconrel.2023.02.015 – volume: 14 year: 2019 ident: B12 article-title: Nanoparticle systems for cancer vaccine publication-title: Nanomed (Lond) doi: 10.2217/nnm-2018-0147 – volume: 168 start-page: 1114 year: 2017 ident: B36 article-title: Modified mRNA Vaccines Protect against Zika Virus Infection publication-title: Cell doi: 10.1016/j.cell.2017.02.017 – volume: 131 start-page: 16 year: 2021 ident: B54 article-title: From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases publication-title: Acta Biomater doi: 10.1016/j.actbio.2021.06.023 – volume: 148 year: 2022 ident: B22 article-title: Guidelines for advancing theory and practice through bibliometric research publication-title: J Bus Res doi: 10.1016/j.jbusres.2022.04.042 – volume: 12 start-page: 2041 year: 2021 ident: B72 article-title: Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via Plug-and-Display technology publication-title: Nat Commun doi: 10.1038/s41467-021-22308-8 – volume: 383 year: 2020 ident: B45 article-title: Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine publication-title: New Engl J Med doi: 10.1056/NEJMoa2026920 – volume: 22 start-page: 41 year: 2021 ident: B77 article-title: Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells publication-title: Nat Immunol doi: 10.1038/s41590-020-00810-3 – volume: 30 year: 2022 ident: B62 article-title: Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine publication-title: Mol Ther doi: 10.1016/j.ymthe.2022.02.001 – volume: 14 start-page: 6195 year: 2023 ident: B64 article-title: Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive antibody response against diverse coronavirus subgenera publication-title: Nat Commun doi: 10.1038/s41467-023-41661-4 – volume: 133 year: 2021 ident: B20 article-title: How to conduct a bibliometric analysis: An overview and guidelines publication-title: J Bus Res doi: 10.1016/j.jbusres.2021.04.070 – volume: 591 year: 2021 ident: B51 article-title: NIH will invest $1 billion to study ‘long covid’ publication-title: Nature doi: 10.1038/d41586-021-00586-y – volume: 35 start-page: e2209910 year: 2023 ident: B74 article-title: Acid-ionizable iron nanoadjuvant augments STING activation for personalized vaccination immunotherapy of cancer publication-title: Adv Mater doi: 10.1002/adma.202209910 – volume: 24 year: 2018 ident: B73 article-title: Mitigating SOX2-potentiated immune escape of head and neck squamous cell carcinoma with a STING-inducing nanosatellite vaccine publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-2807 – volume: 93 year: 2017 ident: B49 article-title: The application of self-assembled nanostructures in peptide-based subunit vaccine development publication-title: Eur Polymer J doi: 10.1016/j.eurpolymj.2017.02.014 |
| SSID | ssj0000493335 |
| Score | 2.383945 |
| Snippet | The emergence of nanotechnology has injected new vigor into vaccine research. Nanovaccine research has witnessed exponential growth in recent years; yet, a... BackgroundThe emergence of nanotechnology has injected new vigor into vaccine research. Nanovaccine research has witnessed exponential growth in recent years;... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 1420216 |
| SubjectTerms | bibliometric Bibliometrics cancer COVID-19 COVID-19 - prevention & control COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - immunology Humans Immunology lipid nanoparticles nanoparticles Nanostructures Nanotechnology SARS-CoV-2 - immunology vaccine Vaccines - administration & dosage |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYhUMgl9Jm6bYIKvbUm1ssr9ZaEhtBDTw3kpkojmWxptKHxBvrvO2Ntwm4o9BJ8kC0bPP5Gj2-s0QxjH0D2QzIxtdYGNFCGINuIxLi1oLKe5dB3afK2-NafneuvF-ZiLdUX-YTV8MAVuMNOheSi6MC6oGcOj6ijTlamAZwSQKMvznlrxtTPynuVUqbukkErzB0O86urJdqDUuPggAUlOF-biaaA_f9imQ-dJddmn9OnbHdFG_lRFfcZ28rlOXtSE0n-ecF-HPE4j79oKz1F3OfzckNGN5bjgpdQFshLa1PDKn4bgJbTP_Nxcoj9xDcaA16HkngNNsIp2zxK-pKdn375fnLWrnIntIBfN7YGemOMjEN0yQxd7CPoCFYpMaAuwCHrci670FunE7hZ1h2eI3syFs1rEdQrtl0WJb9mHLqAPAVSJ0LSOglrM3bjPmgAimUPDft4h6O_riEyPJoWhLqfUPeEul-h3rBjgvr-SQpvPVWg0v1K6f5_Sm_Y-ztFeewOtMYRSl4sb7zq0EBC3UvZsL2quPtXKYeyz6RqmN1Q6YYsm3fK_HIKuS2E0sT83jyG9G_ZDiFCf6aFfMe2x9_LvI_UZowHUyv-C-sB-OU priority: 102 providerName: Directory of Open Access Journals |
| Title | A bibliometric insight into nanomaterials in vaccine: trends, collaborations, and future avenues |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39188723 https://www.proquest.com/docview/3097493322 https://pubmed.ncbi.nlm.nih.gov/PMC11345159 https://doaj.org/article/03ad9b10c89a479797b4b4d82dfc931c |
| Volume | 15 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZKKyQuCFoeC6VyJW4QiB9xbKQKFURbIZUTK-3N-JWyqHXa3Syi_56xk60IKgcUKY6dKLbHM5pv_JhB6KWjovGV9YWUBgyUxtDCAjAupGOB18GI0ufdFl_EyZR_nlWzDbQOdzQQcHmraZfiSU0X529-XV2_B4E_SBYn6Nu3zfziYgWmHuUg95AQcQdtgWaqU0SD0wHu_-jRMGM55iYRghfAy7w_R_OP34x0VXbpfxsO_Xs75R_66egBuj8AS3zYc8JDtBHiNrrbh5q83kHfDrGd2_N02D755MfzuExmOaRdi6OJLSDXnhmhCP80Li24v8Nd3jL7Go_YBfImety7I8EpHj209BGaHn36-vGkGKIrFA561xWVE1VVUdtY5aumtMI6bp1kjDQwWk4BLlMqKCOk4t6pOvASngFfVRIMcGLYY7QZ2xieIuxKA0jG-ZIYz7knUgYQdGG4c8nbvZugV2s66sveiYYG4yNRXWeq60R1PVB9gj4kUt98mRxg54J2caYHedIlM15ZUjqpDK8VXJZb7iX1jVOMQJX764HSIDBpFcTE0K6WmpVgQgEfUDpBT_qBu6mKKWh7TdkEydGQjtoyfhPn37NTbkIYT9jw2X_19Tm6l7JpkprQXbTZLVbhBaCczu7l2QG4H8_IXmbj3_lB_H8 |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+bibliometric+insight+into+nanomaterials+in+vaccine%3A+trends%2C+collaborations%2C+and+future+avenues&rft.jtitle=Frontiers+in+immunology&rft.au=Wu%2C+Beibei&rft.au=Liu%2C+Ye&rft.au=Zhang%2C+Xuexue&rft.au=Luo%2C+Ding&rft.date=2024-08-12&rft.issn=1664-3224&rft.eissn=1664-3224&rft.volume=15&rft_id=info:doi/10.3389%2Ffimmu.2024.1420216&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fimmu_2024_1420216 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon |